0

WHY THIS MATTERS IN BRIEF

Diabetes is quickly becoming one of the world’s top afflictions, and 3D printing could offer an on demand solution to end it forever.

 

Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential Universityconnect, watch a keynote, or browse my blog.

Over the past couple of years there have been a number of breakthroughs in 3D Bio-Printing human organs and tissues on demand including bones, brain tissue, cartilage, corneas, hearts, kidneys, muscle, skin, and more.

 

RELATED
DNA printers get ready to move from printing sentences to paragraphs

 

Now, in another development EPFL spin off Readily3D have announced they’ve developed a new system that can print biological tissue in just 30 seconds and that it’s already being used in a large scale European project that aims to 3D print a living model of the pancreas which can then be used to test new drugs and in time help cure diabetes by providing people in need with replacement organs – note the word curing not just treating …

 

See how it works

 

The first time you see the new model it’s a transparent shape on a computer screen – a small electronic replica of the human pancreas. Then just 30 seconds later the tissue is printed out on a bio-printer, blood vessels and all, from a sample of human stem cells.

 

RELATED
A new artificial human skin gives people spiderman like superpowers

 

The pancreas is a vital organ located just behind the stomach. It serves several functions, such as producing enzymes and bicarbonates essential for digestion and secreting a variety of hormones – including insulin, which is the hormone that regulates blood sugar levels. As a result, pancreatic disease often leads to diabetes since the damaged cells can no longer produce the insulin the body needs.

Over 450 million adults around the world suffer from diabetes, including 60 million in Europe. In Switzerland, 4.4% of the population reported in 2017 having been diagnosed with the disease. And the number of patients is growing worldwide. Diabetes is the second-leading cause of amputation behind accidents and increases the risk of a heart attack or stroke by a factor of eight and of kidney failure, which requires dialysis, by a factor of nine. Diabetes is also the leading cause of blindness among adults. Methods for improving diabetes diagnosis and treatment could thus bring major benefits to public health.

 

RELATED
Scientists use CRISPR to alter the genomes of fruit flies so they can eat poison

 

The bio-printing technology developed at EPFL uses a biological gel containing a patient’s stem cells. A laser is applied to the gel to solidify it through polymerisation. The location and intensity of the laser beam can be controlled in order to solidify only those areas of the gel needed to form the desired tissue.

“One of the main advantages of our method is that it can create tissue in a single block, making it particularly useful for printing soft tissue like human organs,” says Paul Delrot, the CTO of Readily3D.

There are numerous benefits to bio-printed tissue. It can be tailor-made since it’s created from a patient’s own stem cells, and it eliminates the need to conduct animal testing – something that AI, Humans on Chips, and creating digital twins of humans is also trying to accomplish.

 

RELATED
World's first in vivo human gene editing trial goes without a hitch

 

“What’s more, patients won’t have to try out an array of drugs, some of which may have unpleasant side effects, before finding the right one for them,” says Damien Loterie, the CEO of Readily3D.

“Developing a system that can print 3D tissue at the cubic centimeter scale and faithfully replicate the functioning of a live pancreas is a huge challenge, which we hope to meet with this technology,” says Christophe Moser, an associate on the project. And, in time the team hopes they’ll be able to expand their technology so it can be used to bio-print all kinds of other tissues including treatments for cancer, for example, or eventually for producing human transplant organs on demand.

About author

Matthew Griffin

Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.

Your email address will not be published. Required fields are marked *